Genta Incorporated
Genta Updates Progress of its Phase 3 Trial of Genasense in Patients with Advanced Melanoma
Published in Medical Verdicts and Law Weekly, July 10th, 2008
Genta Incorporated (BULLETIN BOARD: GNTA) announced the presentation of a progress update from an ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, the Company's lead oncology product, in patients with advanced melanoma. The data were presented at a satellite investigator's meeting held in conjunction with the Adjuvant Melanoma Congress sponsored by the European Association of Dermato-Oncology (EADO) in Marseille, France on June 21, 2008.
AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- AARP New York
AARP to Host Town Hall Meetings on Prescription Drug Marketing Reform - AARP New York State
Strengthened Identity Theft Protection Laws Will Help Consumers - AC Coin & Slot
AC Coin & Slot and TC Millwork File Patent Infringement Lawsuit Against KGM Gaming - Acacia Research Corporation
Acacia Subsidiary Licenses Fraud Protection Technology to Full Spectrum - ADC
ADC Files Patent Infringement Lawsuit Against AFL Telecommunications - Albo & Oblon, L.L.P.
H. Morgan Griffith to Join Albo & Oblon, L.L.P. - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
